Albemarle Corporation reported better-than-expected second-quarter earnings for 2025, with revenue reaching $1.33 billion compared to estimates of $1.22 billion and adjusted earnings per share of $0.11 versus an anticipated loss of $0.78. The company attributed its performance to increased lithium volume demand. Despite the positive earnings, Albemarle has reduced its full-year capital expenditure outlook to a range of $650 million to $700 million. The firm maintains its full-year earnings assumptions based on a lithium price of $9 per kilogram, contingent on current market conditions. Albemarle also expects to generate positive free cash flow in 2025. In response to a slump in lithium prices, the company has implemented cost-cutting measures to manage expenses. Other companies mentioned include Cytokinetics, Sanofi, BridgeBio Pharma, Atyr Pharma, Rezolute, and Ocugen, which have upcoming earnings calls or clinical trial updates scheduled, but no further financial details were provided for these entities.